RougeTx raises $58M Series A for first HHT treatment

RougeTx, a Leiden University Medical Center spin-off based in Naarden, has launched with a $58 million Series A co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners to take RTX-001, a potential once-daily oral treatment for hereditary haemorrhagic telangiectasia (HHT), towards its first human trials.

We keep hearing that Europe cannot fund biotech company creation at scale – that a preclinical startup here begins life on a grant and a prayer. And yet a university spin-off just opened its doors in the Netherlands with $58 million and a syndicate drawn from three countries plus the European Investment Bank. Below, I lay out the round, the twenty years of science behind it, and what this syndicate says about where European biotech money is flowing.

A $58 million launch built across three countries

RougeTx announced the Series A on 6 October 2026. Founding investor BioGeneration Ventures co-led the round from the Netherlands, alongside Italy’s Angelini Ventures and Paris-based Kurma Partners. Aurea, the co-investment vehicle through which the European Investment Bank participates alongside Angelini Ventures, joined them, as did Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest and Kerna Ventures.

The money has one job: carry RTX-001, the company’s lead programme, towards first-in-human clinical development for HHT. “The data we have generated for RTX-001 gives us a strong foundation as we move toward the clinic,” said CEO Andrew Lightfoot in the announcement. “This financing also allows us to explore where the same biology may impact other vascular diseases.”

The round also fills the boardroom: Edward van Wezel (BioGeneration Ventures), Regina Hodits (Angelini Ventures), Hadrien Bouchez (Kurma Partners), Elizabeth Roper (Epidarex Capital) and Stephane Verdood (Vesalius Biocapital Partners) all join the board of the Naarden-based company.

Twenty years of pericyte science out of Leiden

RougeTx is built on the work of co-founder and scientific advisor Franck Lebrin – more than twenty years of research that began at Inserm and continued for the past decade in his lab at Leiden University Medical Center. The target is the pericyte, the cell that wraps around small blood vessels and keeps them stable.

In HHT, that stability fails. The company describes HHT as the second most common inherited bleeding disorder, affecting around 1.4 million people worldwide (RougeTx’s own figures). Fragile, malformed vessels rupture, causing recurrent nosebleeds, gastrointestinal bleeding, iron deficiency and chronic anaemia; in severe cases, arteriovenous malformations reach the brain, lungs and liver. There is no approved therapy anywhere – patients manage with supportive care and drugs borrowed off-label from oncology.

The good news is that the biology is catching up with the disease. RTX-001 is designed as a once-daily pill that stabilises fragile vessels by restoring pericyte attachment, and behind it sits periSCOPE, the company’s platform for turning the same vascular biology into a pipeline of small-molecule candidates for other diseases driven by vascular instability. Executive chair Sandra Glucksmann frames the stakes plainly: “For too long, people living with HHT have faced a serious, lifelong disease with no approved treatment options.”

A $620 million market waiting for its first approved drug

So what is a first-in-class drug worth in a market built entirely on workarounds? The global HHT market – today essentially off-label treatment and supportive care – was worth $620.5 million in 2024 and is projected to reach $849.2 million by 2032, a 4.0% CAGR over 2025-2032 (Data Bridge Market Research, May 2026). A modest curve by tech standards – but nobody prices a first-in-class orphan drug off a CAGR. The prize is being the only approved option in a market where every dollar currently flows to stopgaps.

For scale from our own records: Sensible Biotechnologies closed a $47M Series A for cell-made mRNA the same week, and Paris-based WhiteLab Genomics raised a $26M Series B for AI-designed genomic medicines. At $58 million, RougeTx lands among the largest European biotech launch rounds in our fundraising data this autumn.

What a Dutch-Italian-French syndicate signals

The reality is that European biotech launches of this size used to wait for a deep-pocketed US lead. What we are seeing instead is a different architecture: a founding investor incubating university science (BioGeneration Ventures around LUMC’s pericyte work), co-leads sharing the risk across borders, regional development capital (ROM Utrecht Region) sitting next to specialist funds, and the European Investment Bank arriving inside the equity syndicate through Aurea rather than waiting at the loan desk. The $58 million did not need San Francisco; it was assembled between the Netherlands, Italy and France.

What to watch now: RTX-001 reaching its first-in-human milestone, and whether periSCOPE produces a second programme – the test of whether RougeTx is a single-asset story or a platform. Watch the syndicate model too; if it holds through the clinic, it is a repeatable answer to Europe’s growth-capital gap in biotech.

Europe does not need to copy Boston’s chequebook to build first-in-class biotech. It needs to keep doing exactly this – patient university science, syndicates that cross borders, and public capital that shows up as equity. HHT patients have waited decades for a first drug. Let’s get it to the clinic!